PE20151746A1 - Compuestos biciclicos - Google Patents
Compuestos biciclicosInfo
- Publication number
- PE20151746A1 PE20151746A1 PE2015001795A PE2015001795A PE20151746A1 PE 20151746 A1 PE20151746 A1 PE 20151746A1 PE 2015001795 A PE2015001795 A PE 2015001795A PE 2015001795 A PE2015001795 A PE 2015001795A PE 20151746 A1 PE20151746 A1 PE 20151746A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- diseases
- bicycle compounds
- bicycle
- slowing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
- C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
Se describen compuestos de la Formula (I); y/o una sal de los mismos; en donde R es -OH u -OP(O) (OH)2. Tambien se refieren a composiciones farmaceuticas.E´stos compuestos actuan como agonistas selectivos del receptor S1P1 acoplado a la proteina G, y son utiles para el tratamiento, la prevencion o la ralentizacion de la progresion de enfermedades o trastornos en varias areas terapeuticas, tales como enfermedades autoinmunes y vasculares
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361767531P | 2013-02-21 | 2013-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151746A1 true PE20151746A1 (es) | 2015-12-02 |
Family
ID=50272738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001795A PE20151746A1 (es) | 2013-02-21 | 2014-02-21 | Compuestos biciclicos |
Country Status (35)
Country | Link |
---|---|
US (3) | US9115054B2 (es) |
EP (1) | EP2958888B1 (es) |
JP (1) | JP6277210B2 (es) |
KR (1) | KR102242265B1 (es) |
CN (1) | CN105026362B (es) |
AR (1) | AR094851A1 (es) |
AU (1) | AU2014218883B2 (es) |
BR (1) | BR112015019919A2 (es) |
CA (1) | CA2902168C (es) |
CL (1) | CL2015002358A1 (es) |
CY (1) | CY1118641T1 (es) |
DK (1) | DK2958888T3 (es) |
EA (1) | EA025294B1 (es) |
ES (1) | ES2613262T3 (es) |
HK (1) | HK1218111A1 (es) |
HR (1) | HRP20170247T1 (es) |
HU (1) | HUE031626T2 (es) |
IL (1) | IL240613B (es) |
LT (1) | LT2958888T (es) |
MA (1) | MA38425B1 (es) |
MX (1) | MX2015010347A (es) |
MY (1) | MY173990A (es) |
PE (1) | PE20151746A1 (es) |
PH (1) | PH12015501793A1 (es) |
PL (1) | PL2958888T3 (es) |
PT (1) | PT2958888T (es) |
RS (1) | RS55703B1 (es) |
SG (1) | SG11201506408TA (es) |
SI (1) | SI2958888T1 (es) |
SM (1) | SMT201700115B (es) |
TN (1) | TN2015000356A1 (es) |
TW (1) | TWI613182B (es) |
UY (1) | UY35338A (es) |
WO (1) | WO2014130752A2 (es) |
ZA (1) | ZA201506965B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015009731A2 (en) | 2013-07-15 | 2015-01-22 | The Regents Of The University Of California | Azacyclic constrained analogs of fty720 |
MA40082B1 (fr) * | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
JP6853539B2 (ja) | 2015-09-24 | 2021-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法 |
CN110234633A (zh) | 2016-09-02 | 2019-09-13 | 百时美施贵宝公司 | 取代的三环杂环化合物 |
WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | OXIME ETHER COMPOUNDS |
WO2021062168A1 (en) * | 2019-09-25 | 2021-04-01 | The Regents Of The University Of California | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
CA2477423A1 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
CA2524048C (en) | 2003-05-19 | 2013-06-25 | Irm Llc | Immunosuppressant compounds and compositions |
JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | S1P(Edg)受容体作働薬としての(3,4−ジ置換)プロパンカルボン酸 |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
MX2007009848A (es) | 2005-02-14 | 2008-03-10 | Univ Virginia | Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo. |
US20060199853A1 (en) | 2005-02-18 | 2006-09-07 | Charles Mioskowski | Analogs of 4-hydroxyisoleucine and uses thereof |
EP1858889A1 (en) | 2005-03-08 | 2007-11-28 | Biota Scientific Management Pty. Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
RU2404178C2 (ru) | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
AU2006256968A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands |
AU2006283175A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
JP5432526B2 (ja) | 2006-01-06 | 2014-03-05 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害剤としてのシクロアルキルアミン |
RU2008134702A (ru) | 2006-01-27 | 2010-03-10 | Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) | Способ лечения невропатической боли |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
CA2645639A1 (en) | 2006-03-23 | 2007-10-04 | Merck & Co. Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
ES2453372T3 (es) | 2006-04-03 | 2014-04-07 | Astellas Pharma Inc. | Derivados de oxadiazol como agonistas de S1P1 |
JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
CA2661315C (en) | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
TW200838497A (en) * | 2006-12-21 | 2008-10-01 | Abbott Lab | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
RU2473545C2 (ru) | 2007-02-02 | 2013-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс |
DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
AU2008306885B2 (en) | 2007-10-04 | 2013-12-05 | Merck Serono S.A. | Oxadiazole derivatives |
AU2008320374A1 (en) | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
ES2431354T3 (es) | 2008-04-01 | 2013-11-26 | Theravance, Inc. | Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu |
CA2739901A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
BRPI0923178A2 (pt) | 2008-12-18 | 2016-02-16 | Merck Serono Sa | derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla |
EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
JP2012515789A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | スフィンゴシン−1−リン酸アゴニストとしてのピラゾール−1,2,4−オキサジアゾール誘導体 |
WO2010085582A1 (en) * | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
US8354398B2 (en) | 2009-01-23 | 2013-01-15 | Bristol-Myers Squibb Company | Substituted isoxazole compounds |
JP2012517445A (ja) | 2009-02-10 | 2012-08-02 | アボット・ラボラトリーズ | S1p受容体アゴニストおよびアンタゴニストを調製するための方法 |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
EP2597089A1 (en) | 2009-10-29 | 2013-05-29 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
CN102260178A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
US9682078B2 (en) | 2011-03-18 | 2017-06-20 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
EP2541155B1 (en) | 2011-04-26 | 2016-02-24 | Panasonic Intellectual Property Management Co., Ltd. | Heating system, and heating system control method |
GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
BR112015001613B1 (pt) | 2012-07-27 | 2021-02-23 | Biogen Ma Inc | compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica |
-
2014
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko active IP Right Grant
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja active Active
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en active Application Filing
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh active Active
-
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793A1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
-
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
- 2016-05-27 HK HK16106055.1A patent/HK1218111A1/zh not_active IP Right Cessation
-
2017
- 2017-02-16 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009673A (es) | Moduladores de ror-gamma. | |
PE20151746A1 (es) | Compuestos biciclicos | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CO2018002060A2 (es) | Compuestos farmacéuticos | |
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
CL2015002188A1 (es) | Agentes analgésicos oculares tópicos | |
WO2015044961A3 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
ECSP15025570A (es) | Formulaciones de pidotimod | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |